(Q38591478)

4 September 2017

1 reference

title

Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders (English)

1 reference

4 September 2017

Nashel DJ

1

1 reference

4 September 2017

publication date

1 July 1985

1 reference

Medical Clinics of North America

4 September 2017

published in

1 reference

4 September 2017

volume

69

1 reference

4 September 2017

issue

4

1 reference

4 September 2017

page(s)

817-840

1 reference

Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Systemic lupus erythematosus and neoplasia of the lymphoreticular system

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Methotrexate therapy in polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine therapy in polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Comparison of intra-articular methotrexate with intra- articular triamcinolone hexacetonide by thermography

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

The clinical pharmacology of methotrexate.new applications of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Treatment of Wegener's granulomatosis with Imuran

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Prednisone and azathioprine for polymyositis: long-term followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine with prednisone for polymyositis. A controlled, clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Low dose, long-term treatment of rheumatoid arthritis with azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Dermatomyositis and multiple malignancies in a patient treated with methotrexate.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Chlorambucil and leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Systemic Rheumatic Disease and Malignant Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Increased numbers of active B cells in the circulation of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Long-term azathioprine in rheumatoid arthritis: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyt

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Dermatomyositis: observations on the use of immunosuppressive therapy and review of literature. Cairo--Glasgow study group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide-induced remissions in advanced polyarteritis nodosa

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide in Treatment of Systemic Lupus Erythematosus: 7 Years' Experience

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Two processes for B-Cell triggering by T-independent antigens as evidenced by the effect of azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Acute myelofibrosis in progressive systemic sclerosis. Report of a case developing during long term chlorambucil therapy and discussion of pathogenetic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Long‐term cyclophosphamide treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine-associated acute pancreatitis in the course of chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Comparison of therapeutic and immunosuppressive effects of azathioprine, prednisolone and combined therapy in NZP-NZW mice

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

A combined clinical and immunological assessment of four cyclophosphamide regimes in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Letter: Intra-articular methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Carcinoma of the bladder in a patient treated with cyclophosphamide for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Serum IgA concentration and hepatotoxicity in rheumatoid arthritis treated with azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cell-mediated immunity to myoglobin in polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Methotrexate therapy in rheumatoid arthritis: 15 years experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Risk of cancer in renal-transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Intermittent cyclophosphamide in refractory rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Studies on the anti-inflammatory action of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Abnormalities of immune regulation in the connective tissue diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Treatment of Reiter's Syndrome with Methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Effects of variation in time and dose of cyclophosphamide injection on delayed hypersensitivity and antibody formation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

The incidence of malignant disease in patients receiving cytotoxic therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

The effect of alkylating agents on the reproductive and hormonal testicular function in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Chromosome Aberrations in the Child of a Kidney Transplant Recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Immunosuppressive and corticosteroid therapy of polyarteritis nodosa

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

A Sequential Trial Comparing Cyclophosphamide and Azathioprine as Adjuncts in the Treatment of Systemic Lupus Erythematosus*

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Treatment of Lupus Nephritis With Azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Treatment of dermatomyositis with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Intra-articular methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Late hemorrhagic cystitis following low-dose cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Treatment of Acute Lupus Pneumonitis with Azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Polymyositis and Dermatomyositis: Combined Methotrexate and Corticosteroid Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Weekly intravenous methotrexate in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Relationship between systemic lupus erythematosus T cell subsets, anti-T cell antibodies, and T cell functions

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Immunopathological changes during immunosuppressive treatment of glomerulonephritis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide Therapy in Wegener's Granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide therapy and interstitial pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Description of a serological reaction characteristic of polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

The clinical pharmacology of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Inductionin vitro of reversible immunosuppression and inhibition of B cell receptor regeneration by defined metabolites of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Exacerbation of Systemic Lupus Erythematosus after Withdrawal of Azathioprine Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Successful treatment of patients with systemic lupus erythematosus, including nephritis, using chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Methotrexate-induced pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide: should it be used daily, monthly, or never?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide in lupus nephritis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cytotoxic drugs in treatment of nonmalignant diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

The anti-inflammatory effect of some immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Psoriasis, methotrexate, and oligospermia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Development of reticulum cell sarcoma during cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Controlled trial of cyclophosphamide in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Long-term effects of azathioprine in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Accelerated appearance of neoplasms in female nzb/nzw mice treated with high-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Adrenocortical carcinoma in a patient with systemic lupus erythematosus treated with azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cytotoxic drug-induced pulmonary disease: update 1980.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Cyclophosphamide-Associated Leukemia in Wegener's Granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Methotrexate in the treatment of rheumatoid arthritis; pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Reappraisal of the use of methotrexate in rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931021-5

7 January 2021

10.1016/S0025-7125(16)31021-5

Identifiers

DOI

0 references

1 reference